We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What Makes Chemours (CC) Stock a Solid Choice Right Now
Read MoreHide Full Article
The Chemours Company’s (CC - Free Report) shares have shot up roughly 33% over the past three months. It is gaining from a rebound in demand from the coronavirus-induced slowdown and its cost-cutting actions.
We are positive on the company’s prospects and believe that the time is right for you to add the stock to the portfolio as it looks promising and is poised to carry the momentum ahead.
Chemours currently sports a Zacks Rank #1 (Strong Buy) and a VGM Score of B. Our research shows that stocks with a VGM Score of A or B, combined with a Zacks Rank #1 or 2 (Buy), offer the best investment opportunities for investors.
Let's see what makes this chemical maker an attractive investment option at the moment.
Price Performance
Shares of Chemours have surged 48.8% year to date against the 9.8% rise of its industry. It has also outperformed the S&P 500’s 14.2% rise over the same period.
Estimates Northbound
Over the past two months, the Zacks Consensus Estimate for Chemours for the current year has increased around 10.7%. The consensus estimate for 2021 has also been revised 26.6% upward over the same time frame. The favorable estimate revisions instill investor confidence in the stock.
Positive Earnings Surprise History
Chemours has outpaced the Zacks Consensus Estimate in each of the trailing four quarters. In this time frame, it has delivered an earnings surprise of 54.1%, on average.
Attractive Valuation
Valuation looks attractive as Chemours’ shares are currently trading at a level that is lower than the industry average, suggesting that the stock still has upside potential.
Going by the EV/EBITDA (Enterprise Value/ Earnings before Interest, Tax, Depreciation and Amortization) multiple, which is often used to value chemical stocks, Chemours is currently trading at trailing 12-month EV/EBITDA multiple of 7.31, cheaper compared with the industry average of 9.77.
Superior Return on Equity (ROE)
ROE is a measure of a company’s efficiency in utilizing shareholder’s funds. ROE for the trailing 12-months for Chemours is 46.3%, above the industry’s level of 9%.
Growth Drivers in Place
Chemours is benefiting from a recovery in demand across its markets, cost-management initiatives and strong execution. In its Fluoroproducts segment, the company is seeing improved customer demand for refrigerants, especially in the automotive sector on a rebound in automotive OEM production rates. It is also witnessing demand recovery in architectural coatings, laminates and plastics markets in its Titanium Technologies segment.
Chemours is also benefiting from increasing adoption of the Opteon platform and growing applications of fluoropolymers, especially in automotive, electronics and energy end-markets. The company is seeing higher demand for Opteon in mobile applications. It remains committed to drive Opteon adoption. It is ramping up production at the new low-cost Opteon Corpus Christi facility.
Moreover, the company stands to gain from its efforts to reduce costs. It is taking actions to cut costs by reducing overhead, discretionary spend and capital expenditure for 2020. These actions are helping it to generate strong cash flows. Chemours aims to cut costs by $160 million and capital expenditure by roughly $125 million in 2020. The company’s cost and operational improvement actions across its businesses are expected to support its margins.
Other top-ranked stocks worth considering in the basic materials space include Bunge Limited (BG - Free Report) , Impala Platinum Holdings Limited (IMPUY - Free Report) and BHP Group (BHP - Free Report) .
Bunge has an expected earnings growth rate of 43.5% for the current year. The company’s shares have gained around 12% in the past year. It currently carries a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Impala Platinum has an expected earnings growth rate of 131.7% for the current fiscal. The company’s shares have rallied around 31% in the past year. It currently carries a Zacks Rank #1.
BHP Group has a projected earnings growth rate of 43.3% for the current fiscal year. The company’s shares have gained around 19% in a year. It currently carries a Zacks Rank #2.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.4% per year.
These 7 were selected because of their superior potential for immediate breakout.
Image: Bigstock
What Makes Chemours (CC) Stock a Solid Choice Right Now
The Chemours Company’s (CC - Free Report) shares have shot up roughly 33% over the past three months. It is gaining from a rebound in demand from the coronavirus-induced slowdown and its cost-cutting actions.
We are positive on the company’s prospects and believe that the time is right for you to add the stock to the portfolio as it looks promising and is poised to carry the momentum ahead.
Chemours currently sports a Zacks Rank #1 (Strong Buy) and a VGM Score of B. Our research shows that stocks with a VGM Score of A or B, combined with a Zacks Rank #1 or 2 (Buy), offer the best investment opportunities for investors.
Let's see what makes this chemical maker an attractive investment option at the moment.
Price Performance
Shares of Chemours have surged 48.8% year to date against the 9.8% rise of its industry. It has also outperformed the S&P 500’s 14.2% rise over the same period.
Estimates Northbound
Over the past two months, the Zacks Consensus Estimate for Chemours for the current year has increased around 10.7%. The consensus estimate for 2021 has also been revised 26.6% upward over the same time frame. The favorable estimate revisions instill investor confidence in the stock.
Positive Earnings Surprise History
Chemours has outpaced the Zacks Consensus Estimate in each of the trailing four quarters. In this time frame, it has delivered an earnings surprise of 54.1%, on average.
Attractive Valuation
Valuation looks attractive as Chemours’ shares are currently trading at a level that is lower than the industry average, suggesting that the stock still has upside potential.
Going by the EV/EBITDA (Enterprise Value/ Earnings before Interest, Tax, Depreciation and Amortization) multiple, which is often used to value chemical stocks, Chemours is currently trading at trailing 12-month EV/EBITDA multiple of 7.31, cheaper compared with the industry average of 9.77.
Superior Return on Equity (ROE)
ROE is a measure of a company’s efficiency in utilizing shareholder’s funds. ROE for the trailing 12-months for Chemours is 46.3%, above the industry’s level of 9%.
Growth Drivers in Place
Chemours is benefiting from a recovery in demand across its markets, cost-management initiatives and strong execution. In its Fluoroproducts segment, the company is seeing improved customer demand for refrigerants, especially in the automotive sector on a rebound in automotive OEM production rates. It is also witnessing demand recovery in architectural coatings, laminates and plastics markets in its Titanium Technologies segment.
Chemours is also benefiting from increasing adoption of the Opteon platform and growing applications of fluoropolymers, especially in automotive, electronics and energy end-markets. The company is seeing higher demand for Opteon in mobile applications. It remains committed to drive Opteon adoption. It is ramping up production at the new low-cost Opteon Corpus Christi facility.
Moreover, the company stands to gain from its efforts to reduce costs. It is taking actions to cut costs by reducing overhead, discretionary spend and capital expenditure for 2020. These actions are helping it to generate strong cash flows. Chemours aims to cut costs by $160 million and capital expenditure by roughly $125 million in 2020. The company’s cost and operational improvement actions across its businesses are expected to support its margins.
The Chemours Company Price and Consensus
The Chemours Company price-consensus-chart | The Chemours Company Quote
Stocks to Consider
Other top-ranked stocks worth considering in the basic materials space include Bunge Limited (BG - Free Report) , Impala Platinum Holdings Limited (IMPUY - Free Report) and BHP Group (BHP - Free Report) .
Bunge has an expected earnings growth rate of 43.5% for the current year. The company’s shares have gained around 12% in the past year. It currently carries a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Impala Platinum has an expected earnings growth rate of 131.7% for the current fiscal. The company’s shares have rallied around 31% in the past year. It currently carries a Zacks Rank #1.
BHP Group has a projected earnings growth rate of 43.3% for the current fiscal year. The company’s shares have gained around 19% in a year. It currently carries a Zacks Rank #2.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.4% per year.
These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>